ŞHŞeminur Haznedaroğlu

Şeminur Haznedaroğlu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Şeminur Haznedaroğlu has a total of 104 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • PRDX-4: a novel biomarker similar to KL-6 for predicting the occurrence and progression of systemic sclerosis-ILD

    by Gizem Tuğçe Alp, İbRahim Vasi, Emre Alp, Aslıhan Avanoğlu Güler, Hazan Karadeniz, Özlem Gülbahar, Abdulsamet Erden, Abdurrahman Tufan, Mehmet Akif Öztürk, Berna Göker, et al.

    1. Systemic sclerosis (SSc) is a progressive autoimmune connective tissue disease characterized by vasculopathy, inflammation, and fibrosis [1]. The lungs are among the most affected organs, with i...


  • The frequency of autoimmune disease in the first degree and other relatives of the breast cancer patients

    by Ali Atay, Berna Göker, Mehmet Akif Öztürk, Abdurrahman Tufan, Şeminur Haznedaroğlu, Hakan Babaoğlu, Ahmet Özet, Aytuğ Üner, Nazan Günel, Gözde Tahtacı

  • The assessment of hyposalivation and its impact on mouth disability in systemic sclerosis patients

    by Aslihan Avanoglu Guler, Hazan Karadeniz, Reyhan Bilici, Hasan Satış, Hakan Babaoğlu, Nuh Ataş, Hamit Küçük, Berna Göker, Seminur Haznedaroğlu, Mehmet Akif Öztürk, et al.

  • Exocrine pancreatic dysfunction in systemic sclerosis and primary Sjogren’s syndrome patients

    by Hasan Satış, Burak Arslan, Serdar Can Güven, Reyhan Bilici Salman, Hakan Babaoğlu, Nuh Ataş, Aslıhan Avanoğlu Güler, Hazan Karadeniz, Berna Göker, Şeminur Haznedaroğlu, et al.

  • Open Access

    A real-life analysis of patients with rheumatologic diseases on biological treatments: Data from TURKBIO Registry

    by Ayşe Cefle, Nurullah Akkoç, Haner Direskeneli, Fatih Yıldız, Gözde Yildirim Çetin, Şule Yavuz, Seminur Haznedaroğlu, Berna Göker, Özgül Soysal Gündüz, Cemal Bes, et al.

    Objective: TURKBIO registry, established in 2011, is the first nationwide biological database in Turkey. This study aimed to provide an overview of TURKBIO data collected by June 2018. Methods: The registry included adult patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS), nonradiographic axial spondyloarthritis (nr-AxSpA), and psoriatic arthritis (PsA). Demographic and clinical features, disease activity markers, and other follow-up parameters, current and previous treat- ments, and adverse events were registered electronically at each visit using open-source software. The registration of patient-reported outcome measures was carried out electronically by the patients using touch screens. Results: TURKBIO registry included a total of 41,145 treatment series with biologicals. There were 2,588 patients with axSpA (2,459 AS and 129 nr-axSpA), 2,036 with RA, and 428 with PsA. The total number of patients, including those with other diagnoses, was 5,718. In the follow-up period, the number of patients and also visits steadily increased by years. The yearly mean number of visits per patient was found to be 2.3. Significant improvements in disease activity and health assessment parameters were observed following the biological treatments. Biologics were often given in combination with a con- ventional synthetic disease-modifying antirheumatic drug in patients with RA. Infections were the most commonly seen adverse events, followed by allergic reactions. Tuberculosis was observed in 12 patients, malignancy in 18, and treatment-related mortality in 31. Conclusion: TURKBIO provided a valuable real-life experience with the use of biologics in rheumatic diseases in Turkey. Cite this article as: O€ nen F, Can G, C apar S, et al. A real-life analysis of patients with rheumatologic diseases on biological treatments: Data from TURKBIO Registry.Eur J Rheumatol. 2022;9(2):82-87.


  • Open Access

    Treatment with biologic DMARDs may not adversely affect lung nodules in rheumatoid arthritis patients

    by Hazan Karadeniz, Hakan Babaoğlu, Aslıhan Avanoğlu Güler, Reyhan Bilici Salman, Hasan Satış, Nuh Ataş, Berna Göker, Şeminur Haznedaroğlu, Mehmet Akif Öztürk, Abdurrahman Tufan, et al.

    Objective: Lung nodules (LNs) impose diagnostic and therapeutic challenges in patients with rheuma- toid arthritis (RA) due to unpredictable outcomes. Potential induction of nodulosis with the use of con- ventional synthetic DMARDs (csDMARD) and lack of knowledge regarding the effect of biologic disease-modifying anti-rheumatic drugs (bDMARDs)/tofacitinib on the LN raise concerns and have an impact on treatment decisions. This study aims to evaluate the possible effects of the bDMARDs/tofa- citinib and csDMARDS on LNs observed in RA patients. Methods: Electronic health records of RA patients who had LNs detected on computed tomography (CT) between January 2015 and December 2020 were evaluated retrospectively. Patients with follow- up CT images were included in the study. Baseline and follow-up images were meticulously examined for the number, size, attenuation, and cavity formation. Clinical, histopathologic, and laboratory find- ings were analyzed. Results: Forty-two RA patients with LNs were studied, 21 were on bDMARDs/tofacitinib (11 females, mean age: 59.7 6 8.4) and 21 were on csDMARDs (12 females, mean age: 71.4 6 8.3). The proportion of patients with progressed nodules during follow-up was comparable between groups (six patients in bDMARDs/tofacitinib vs seven patients in csDMARDs). Progression of LNs was observed in six patients in the bDMARDs/tofacitinib group: three in anti-TNFa, two in rituximab, and one in abatacept users and none in tofacitinib users. Conclusion: Our results suggest that the risk of progression in LNs in RA patients with use of bDMARDs/tofacitinib might not impose a higher risk compared to csDMARDs. Moreover, bDMARDs/ tofacitinib might result in regression in LNs. Cite this article as: Karadeniz H, Cindil E, Babaog ̆ lu H, et al. Treatment with bio- logic DMARDs may not adversely affect lung nodules in rheumatoid arthritis patients. Eur J Rheumatol. 2022;9(2):75-81.


  • Open Access

    Factors affecting patient-acceptable symptom states and treatment decision in familial Mediterranean fever

    by Derya Yildirim, İbRahi̇m Vasi̇, Erdi̇ Tahta, Riza Can Kardaş, Burcugül Özkiziltaş, Hami̇t Küçük, Mehmet Aki̇f Öztürk, Şemi̇nUr Haznedaroğlu, Berna Göker, Abdurrahman Tufan

    Background/aim: Familial Mediterranean fever [FMF] is the most common autoinflammatory disease characterized by inflammatory attacks of fever and polyserositis. Patients' quality of life is significantly affected due to recurrent excruciating pain attacks and complications. This study is performed to evaluate the parameters most affecting patients' satisfaction from treatment. Materials and methods: Three hundred and forty-six consecutive patients diagnosed with FMF were enrolled in this study. Current treatment, acute phase proteins, number, type, and severity of predominant attacks, absenteeism from work/school in the last three months were recorded, and the participants were asked whether they needed additional treatment to evaluate Patient Acceptable Symptom State (PASS) status. Results: Mean age of the overall group was 38.2 ± 11.7 years (62.4% female, 37.6% male). Two hundred and twenty-seven patients were treated with colchicine, 97 patients with colchicine plus Interleukin-1 (IL-1) antagonist, and 22 only with IL-1 antagonist (67.1%, 26.3%, 6.64% in order). Of the overall group, 33.8% (n = 117) believed to need additional treatment options. Additional treatment need of patients was significantly affected by work impairment due to attacks, absent days from work, disease activity, the discomfort of patients during attacks, the number of attacks, and treatment options; but not by the level of acute-phase proteins between attacks. Conclusion: PASS score is significantly related to clinical parameters and quality of life. Patients' PASS scores and treatment choices are notably affected by the severity and frequency of attacks and absenteeism from work/school. Clinical activity and quality of life should be evaluated at every visit to provide patients' satisfaction with treatment.


  • Open Access

    Diagnostic utility of serum biomarkers in large vessel vasculitis and their correlation with positron emission tomography

    by Reyhan Bilici Salman, Gülce Koca, Seda Gülbahar Ateş, Dilek Yapar, Hakan Babaoglu, Hasan Satış, Aslıhan Avanoglu Güler, Hazan Karadeniz, Nuh Ataş, Hamit Küçük, et al.

    To investigate the association between vascular inflammation, as detected by positron emission tomography (PET) imaging and interleukin-6 (IL-6), pentraxin3, and B-cell-activating factor (BAFF) in subjects with LVV. The study included newly diagnosed giant cell arteritis (GCA, n = 27) or Takayasu arteritis (n = 9) patients and healthy control (HC, n = 31) subjects. PET scan and blood samples were obtained before the introduction of treatments. IL-6, PTX3, and BAFF levels were determined quantitatively by enzyme-linked immunosorbent assay kits. Thirty-six patients with LVV (20 females, 16 males; age 64.5 ± 16.6 years) and 31 HC (14 females, 17 males; age 37.1 ± 9.6 years) were included. Serum levels of IL-6, PTX3, and BAFF were increased in patients with newly diagnosed LVV compared with healthy control subjects. In receiver operating characteristics (ROC) analysis, serum IL-6 and BAFF provided excellent discrimination of newly diagnosed LVV patients from HC (area under the ROC curve of >0.90 and >0.80, respectively). None of the inflammatory markers correlated with vascular inflammatory activity determined by PET scanning. Our results suggest that IL-6 and BAFF may serve as markers of large vessel vasculitis, while PTX3 is not useful. None of the inflammatory markers correlated with PET assessed vasculitis activity.


  • Sistemik lupus eritematozusda prognostik nutrisyonel indeksin hastalık aktivitesi ile olan ilişkisinin araştırılması: Tek merkez deneyimi

    by Reyhan Bi̇li̇ci̇ Salman, Şeminur Haznedaroğlu

    Amaç: Periferik kandaki serum albümin seviyesi ve lenfosit sayısı ile hesaplanan ve hastaların immün-beslenme durumu yansıtan prognostik nutrisyon indeks (PNI) ile Türkiye’deki SLE hastalarında hastalık aktivitesi (SLEDAI-2K) arasındaki ilişkiyi göstermeyi ve PNI’nın hastalık aktivitesinin bağımsız bir prediktörü olduğunu göstermeyi amaçladık. Yöntem: PNI, 156 SLE hastasında aşağıdaki formüle göre hesaplandı: 10 x serum albümin değeri (g / dL) + 0.005 x periferik lenfosit sayısı (/ mm3). PNI ile laboratuvar değişkenleri arasındaki ilişkilerin analizinde Spearman korelasyon analizi kullanıldı. Laboratuvar ve klinik değişkenler ile SLE Hastalık Aktivite İndeksi-2000 (SLEDAI-2 K) arasındaki ilişkiyi göstermek için lojistik regresyon analizleri yapıldı. Bulgular: 79’u hastalık aktivitesi yüksek (SLEDAI-2K>10)ve 77’si hastalık aktivitesi düşük toplam 156 SLE hastası çalışmaya alındı. Yüksek hastalık aktivitesine sahip SLE hastalarının medyan PNI'si, hastalık aktivitesi düşük olanlar ile kıyaslandığında daha düşük saptanmıştır (38'e karşı 42, p